1.29
0.03 (2.38%)
0.03 (2.38%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 63,772 |
|
|||||
| News | - | ||||||
| Day High | 1.29 | Low High |
|||||
| Day Low | 1.25 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Moleculin Biotech Inc | MBRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 2.38% | 1.29 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.29 | 1.25 | 1.29 | 1.29 | 1.26 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 133 | 63,772 | $ 1.26 | $ 80,591 | - | 0.817 - 2.05 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:35:58 | 1 | $ 1.31 | USD |
Period:
Draw Mode:
Moleculin Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 36.93M | 28.63M | 28.01M | $ - | $ - | -0.59 | -1.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 67.50k | 3.10% |
Moleculin Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MBRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.27 | 1.32 | 1.22 | 1.27 | 41,252 | 0.02 | 1.57% |
| 1 Month | 1.12 | 1.35 | 1.02 | 1.18 | 66,401 | 0.17 | 15.18% |
| 3 Months | 1.02 | 1.51 | 0.817 | 1.25 | 107,731 | 0.27 | 26.47% |
| 6 Months | 1.66 | 1.85 | 0.817 | 1.30 | 101,460 | -0.37 | -22.29% |
| 1 Year | 1.54 | 2.05 | 0.817 | 1.41 | 93,021 | -0.25 | -16.23% |
| 3 Years | 0.91 | 8.78 | 0.323 | 1.88 | 1,441,361 | 0.38 | 41.76% |
| 5 Years | 1.97 | 8.78 | 0.323 | 1.88 | 1,172,632 | -0.68 | -34.52% |
Moleculin Biotech Description
| Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. |